Multiple Sclerosis Journal - Experimental, Translational and Clinical
Overview
Multiple Sclerosis Journal - Experimental, Translational and Clinical is a scientific journal, published since 2015 in English. The journal's country of origin is United States.
Details
Details
Abbr.
Mult Scler J Exp Transl Clin
Start
2015
End
Continuing
e-ISSN
2055-2173
Country
United States
Language
English
Metrics
Metrics
h-index / Ranks: 10631
29
SJR / Ranks: 4073
959
CiteScore / Ranks: 6878
3.90
Recent Articles
1.
Roy S, Haughton J, Vaidya D, Newsome S
Mult Scler J Exp Transl Clin
. 2025 Mar;
11(1):20552173251320791.
PMID: 40034254
Objective: To determine the efficacy of a safety program designed for monitoring infusion disease-modifying therapies (DMTs) prescribed for multiple sclerosis (MS). Background: Infusion-based high-efficacy DMTs represent a major advance in...
2.
Disanto G, Schaedelin S, Oechtering J, Lorscheider J, Galbusera R, Finkener S, et al.
Mult Scler J Exp Transl Clin
. 2025 Feb;
11(1):20552173251315457.
PMID: 40017897
Background: Persistence to B cell depleting therapies (BCDT) like ocrelizumab and rituximab may be higher compared with other disease-modifying therapies (DMT) in multiple sclerosis (MS). Clinical trials directly comparing these...
3.
Diaz-Quiroz M, Chicue-Cuervo P, Garcia-Moreno L, Gaviria-Carrillo M, Talero-Gutierrez C, Palacios-Espinosa X
Mult Scler J Exp Transl Clin
. 2025 Feb;
11(1):20552173241312527.
PMID: 39949505
Introduction: Fatigue is a highly prevalent symptom in people with multiple sclerosis. It demands careful assessment and prompt intervention to improve their quality of life and overall burden of disease....
4.
Makarov C, Donnachie E, Hapfelmeier A, Hemmer B, Gasperi C
Mult Scler J Exp Transl Clin
. 2025 Feb;
11(1):20552173251315458.
PMID: 39944057
Background: Comorbidities in people with multiple sclerosis (PwMS) can affect disease course and quality of life. Objectives: To investigate comorbidities in the five years after diagnosis, timing of comorbidity occurrence,...
5.
Sandesjo F, Alping P, Fink K, Wickstrom R, Piehl F, Frisell T, et al.
Mult Scler J Exp Transl Clin
. 2025 Feb;
11(1):20552173251314118.
PMID: 39931539
Few controlled trials of disease-modifying therapies (DMTs) have been conducted on the pediatric-onset multiple sclerosis (PoMS) population, leading to extensive off-label use of therapies approved only for adults. This highlights...
6.
Acir I, Sezen A, Aygun M, Altintas A
Mult Scler J Exp Transl Clin
. 2025 Feb;
11(1):20552173241312534.
PMID: 39895881
Background: SLIPPERS (Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids) is a rare variant of a syndrome called CLIPPERS (Chronic Lymphocytic Inflammation with Ponsine Perivascular Enhancement Responsive to...
7.
Weber C, Wilbur C, Blevins G, Beaulieu C
Mult Scler J Exp Transl Clin
. 2025 Feb;
11(1):20552173251315161.
PMID: 39895880
Background: Diffusion tensor imaging (DTI) in adults with multiple sclerosis (MS) has identified marked volume and diffusion abnormalities of the fornix, the main white matter (WM) output tract of the...
8.
Teni F, Machado A, Dervish J, Fink K, Gyllensten H, Friberg E
Mult Scler J Exp Transl Clin
. 2025 Jan;
11(1):20552173241304324.
PMID: 39781023
Background: Work ability index (WAI) is an instrument that measures work ability in workplace surveys and health examinations in occupational health and research. It has been used in different population...
9.
Machado A, Pettersson E, Alexanderson K, Hillert J, Friberg E
Mult Scler J Exp Transl Clin
. 2024 Dec;
10(4):20552173241305982.
PMID: 39703812
The prodromal features of multiple sclerosis (MS) are non-specific and are prevalent in the general population. Several studies indicate an increased use of healthcare resources by individuals with MS in...
10.
Beczek A, Landt E, Storr L, Beck M, Pontieri L, Magyari M, et al.
Mult Scler J Exp Transl Clin
. 2024 Dec;
10(4):20552173241307619.
PMID: 39703811
Background: In Denmark, specialized multiple sclerosis (MS) clinics offer free-of-charge treatment to people with MS. However, not all people with MS attend regular clinical follow-up. Objective: To identify people with...